Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New catheter lock could slash infection risk for cancer patients

NCT ID NCT02279121

Prevention Sponsor: Centre Hospitalier Régional Metz-Thionville Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a taurolidine-citrate solution (TauroLock) placed in the catheter between treatments can prevent bloodstream infections in adults with solid tumors receiving IV anti-cancer therapy. 162 patients were randomly assigned to get either the TauroLock solution or standard saline. The main goal was to see how many catheter-related infections occurred in each group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
taurolidine-citrate solution (TauroLock)
What this could lead to
If it works, this could provide a simple way to prevent serious catheter infections in cancer patients on IV therapy.
What could go wrong
This is a completed trial with 162 patients, but results may not apply to all cancer types or settings. The solution may cause side effects or not reduce infections significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

162 people

The number who actually took part.

Start date

Nov 2014

Finished

Mar 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients older than 18 years * Performance Index (WHO score) ≤ 2 * Patient with a solid cancer receiving an IV anti-tumor treatment * Presence of a totally implantable CVC * Anti-tumoral therapy administered by a totally implantable CVC * Metastatic and / or (neo) adjuvant treatment * Full hospitalised and / or day-hospital patients * Informed written consent * Social Health security insurance Exclusion Criteria: * Hematological cancer patients * HIV-positive patients and/ or patients receiving an active immunosuppressive therapy * Patients presenting a febrile episode within 4 days prior to randomisation * Patients with neutropenia grade ≥ 2 (ANC ≤ 1000/mm3) on a blood testing older than 7 days * Patients on IV antibiotic therapy * Patients on total and / or peripheral parental nutrition * Patients with a previous CLABSI history * Allergy to citrate or taurolidine * Patients who are not able to give an informed consent * Patients under guardianship * Patients under judicial protection * Pregnant or breastfeeding woman

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Catheter-related infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Catheter-Related Infections neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Catheter-related infections

Contacts and locations

Locations

  • Chr Metz Thionville

    Metz, 57085, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.